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Abstract
Background: Gonadotropin-releasing hormone agonists 
(GnRH-a) are common treatment options for central 
 precocious puberty (CPP) in childhood. GnRH-a treat-
ment is useful and has a good safety profile, with 
minimal adverse effects and no severe long-term conse-
quences. The common side effects in children are meno-
pause-like symptoms and local adverse events at the 
injection site.
Case presentation: We present the case of a girl with CPP 
who developed arterial hypertension from treatment with 
GnRH-a (triptorelin). Comprehensive diagnostic studies 
ruled out other causes for her hypertension and its com-
plications. After therapy was interrupted, her blood pres-
sure remained within normal limits for age. Consequently, 
we hypothesize that the hypertension presented by our 
patient was related to triptorelin treatment.
Conclusions: Although the etiology of this adverse event 
is not known and only some hypotheses can be made, cli-
nicians should be aware that arterial hypertension might 
appear during triptorelin treatment in childhood with 
CPP. Therefore, they should routinely monitor the arterial 
blood pressure of patients under treatment.
Keywords: arterial hypertension; GnRH-a; precocious 
puberty.
Introduction
Precocious puberty (PP) is defined as the onset of second-
ary sexual development before the age of 8 years in girls 
and 9 years in boys [1]. The PP is traditionally classified 
into two categories: central precocious puberty (CPP) 
and peripheral precocious puberty. Moreover, benign 
and non-progressive pubertal variants, such as prema-
ture adrenarche, premature thelarche, non-progressive 
or intermittently progressive precocious puberty, are also 
known. Classically, CPP is more frequent in females [2].
The presence of clinical signs, a bone age higher than 
chronological age, enlarged ovaries with increased uterine 
size at pelvic ultrasonography and hormonal data evi-
dencing the activation of hypothalamic-pituitary-gonadal 
axis are necessary to confirm the diagnosis [2]. In these 
cases, treatment with gonadotropin-releasing hormone 
agonists (GnRH-a) may be considered. The therapy has 
the following primary short-term goals: to suppress the 
pituitary-gonadal axis and to reduce the development of 
secondary sex characteristics as well as bone age advance-
ment. Long-term goals are to improve final adult height 
and to avoid psychosocial or behavioral problems [3, 4].
GnRH-a treatment is useful and has a good safety 
profile, with minimal adverse effects and no severe long-
term consequences [3–5]. Nevertheless, during treatment, 
patients should be monitored periodically to evaluate 
pubertal development, height velocity and bone age and 
to determine how long the treatment should last [3].
Case presentation
A 7-year-old girl presented to our pediatric endocrinology 
centre with breast enlargement and development of pubic 
hair, which already lasted for 7 months.
She was born at term by vaginal delivery after an 
uneventful pregnancy with an appropriate birth weight. 
The child was breastfed and had regular growth. She had 
no known allergies, and no noteworthy diseases were 
reported in the family history. The maternal menarche was 
reported at 12 years and her target height was 162.5 cm.
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At our first clinical examination, the patient appeared 
in good condition, without dysmorphic features and 
with normal body proportion. Bodyweight was 35.3 kg 
(1.13 standard deviations [SD]), height was 135 cm (1.33 SD; 
90th percentile) and the body mass index (BMI) was 
19 kg/m2 (0.81 SD). Cardiothoracic, abdominal and 
genital eva luations were normal. Blood pressure was 
105/55 mmHg, within the normal range according to sex, 
age and height percentile [6]. She showed acne on her 
back. Her Tanner stage was B3, Ph2.
Pelvic ultrasound showed a longitudinal uterine diam-
eter of 36 mm, whereas bone age was shown to be 2 years 
higher than her chronological age. Hormonal assays 
(beta-human chorionic gonadotropin [β-HCG], dehydroe-
piandrosterone sulfate [DHEAS] Δ4-androstenedione, tes-
tosterone, cortisol, thyroid-stimulating hormone [TSH], 
free thyroxine [FT4]) were normal. A triptorelin stimulation 
test proved the diagnosis of CPP, evidencing a luteinizing 
hormone (LH) peak of 26.4 U/L, with an LH/follicle-stimu-
lating hormone (FSH) ratio of 1.22 and an estradiol level of 
229 pmol/L. A magnetic resonance imaging (MRI) showed 
pituitary and central nervous system to be normal.
According to her parents, she began treatment with 
GnRH-a in a long-acting depot preparation (triptorelin) 
administered at a dose of 3.75 mg every 28 days. During the 
therapy, the patient reported only occasional hot flushes 
and headache. After 6 months, she showed at our endo-
crinological evaluation a slight reduction in the develop-
ment of secondary sexual characteristics (Tanner stage: 
B2, Ph2) and presented a stable BMI (variable between 
0.95 and 0.98 SD) and a stable uterine size at pelvic ultra-
sound (35 mm vs. 36 mm). Her blood pressure remained 
normal according to sex, age and height percentile.
After 1 year and 6  months from the beginning of 
the treatment, we found an elevated blood pressure 
(140/80 mmHg, systolic blood value >99th centile for sex, 
age and height, diastolic blood value >95th centile for sex, 
age and height) without other symptoms. These data were 
confirmed at subsequent controls; we therefore investi-
gated the etiology of this clinical sign.
Blood pressure holter monitoring confirmed hyper-
tension (mean day and night blood pressure values 
>95th centile for sex, age and height; systolic blood 
pressure load 62%, diastolic blood pressure load 83%, 
nocturnal dipping 11.5% [6]). Transthoracic echocar-
diographic and cardiologist and ocular evaluation 
were normal and excluded hypertensive complications. 
Furthermore, renovascular and adrenal diseases were 
excluded because of normal hormonal assays (urinary 
steroids, cortisol, aldosterone, active renine, urinary 
cathecolamine) and normal abdominal ultrasound. 
Finally, renal vascular Doppler ultrasound was normal 
with standard velocimetric parameters in both renal 
arteries. We did not start an antihypertensive treatment, 
but we suggested a management program, emphasizing 
appropriate nutrition, with deprivation of salt, and con-
stant physical exercise.
During treatment, her blood pressure values remained 
elevated in the absence of other symptoms, whereas her 
pubertal signs were stable. Her parents were very worried 
about her hypertension and, after other 6 months of treat-
ment, they decided to stop GnRH-a.
After 2–3  months from interruption of therapy, her 
blood pressure was within the normal limits for sex, 
age and height. A GnRH test, performed 6  months after 
the end of treatment, confirmed hypothalamic-pituitary-
gonadal axis recovery. Her bodyweight was 48.8 kg (1.19 
SD), height was 150 cm (1.20 SD, 90th percentile) BMI was 
21.7 kg/m2 (0.90 SD). Blood pressure holter monitoring was 
repeated and showed normal values (mean day and night 
blood pressure values <50th centile sex, age and height 
[6]; systolic blood pressure load 2%, diastolic blood pres-
sure load 10%, nocturnal dipping 16.1%). Consequently, 
we can hypothesize that hypertension presented by our 
patient was related to GnRH-a treatment.
The study was conducted in compliance with the 
terms of the Helsinki II Declaration. Written informed 
consent was obtained from the parents of the patient.
Discussion
This brief report underlines the risk of arterial hyperten-
sion developing during triptorelin administration for CPP 
in children who were previously normotensive.
GnRH-a treatment is safe and effective and is gen-
erally well tolerated in children and adolescents [3–5]. 
The depot formulations are effective in maintaining the 
suppression of pituitary gonadotropin secretion. During 
the first few weeks after the beginning of the treatment, 
agonist effects can be observed (“flare-up phase”), but 
only by the second month of the therapy, significant inhi-
bition is achieved due to desensitization of the pituitary 
GnRH receptors. Stabilization or regression of clinical 
signs, such as a decrease in the breast size, decline in the 
growth rate and uterine size, is observed in all patients. 
On the contrary, a progression of pubertal signs is indica-
tive of treatment failure [4]. A few days after the initial 
dose of the GnRH-a was administered, vaginal bleed-
ing may occur due to estradiol withdrawal, because the 
treatment initially stimulates estradiol production before 
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suppressing the pituitary gonadal axis. This adverse effect 
is infrequent and disappears spontaneously, without 
further treatment. Other infrequent adverse effects are 
menopausal symptoms, such as headaches, hot flashes 
or emotional lability, which may occur occasionally, but 
they are usually short term and do not interfere with 
the effect of the treatment [4]. Local adverse events like 
erythema and induration may occur on the site of intra-
muscular injection [5]. In some cases, these dermato-
logical problems can result in sterile abscesses. Although 
exceedingly rare, anaphylaxis has been described among 
the adverse events caused by GnRH-a. Gonadal function 
is promptly restored in girls after cessation of the treat-
ment, and reproductive potential appears normal in 
young adulthood. There are conflicting data on the long-
term risk of polycystic ovarian syndrome but the therapy 
does not seem to have any long-term effect on BMI, and a 
negative impact on bone mineral density. At the moment, 
no repercussions are known on the timing of menopause 
and on the health of the offspring [4].
Arterial hypertension is not considered as an adverse 
event correlated to the use of GnRH-a in children with CPP. 
Only recently, two reports have described an elevation of 
blood pressure values in patients treated with GnRH-a [7, 
8], but one patient was affected by Williams-Beuren syn-
drome, that is, a condition associated with an increased 
risk of hypertension. Nevertheless, the authors ruled out 
all potential causes of hypertension related to this syn-
drome and demonstrated a clear association between the 
GnRH-a therapy and this clinical sign [8]. The other report 
presented a case that more closely resembled our situation: 
the patient did not present any predictive factor of arterial 
hypertension and the timing of the appearance of hyper-
tension was similar. The reported authors explained the 
origin of hypertension in a healthy girl as the consequence 
of hypoestrogenism induced by the drug, probably asso-
ciated with genetic predisposition. They, however, did not 
consider the role of adiposity [7]. Moreover, in both cases, 
the severity of hypertension induced the physicians to start 
an antihypertensive treatment with ramipril and nifedipina 
in the first case and amlodipine in the second case. On the 
contrary, in our patient, hypertension was well controlled 
with dietary measures and physical activity.
Our report confirms the hypothesis that a treatment 
with GnRH-a may provoke arterial hypertension. In our 
patient, echocardiography imaging, abdominal ultrasound 
imaging, renal vascular Doppler and hormonal values 
were normal, excluding overt cardiovascular and/or 
renovascular disease, renal parenchymal disease and 
endocrine causes of hypertension. She presented normal 
blood pressure before the treatment and she did not have 
other clinical problems that could cause an increase in 
the blood pressure levels. Finally, her blood pressure was 
completely normalized 6 months after the suspension of 
the treatment. Arterial hypertension was identified after 
a year and a half of treatment, probably because blood 
pressure progressively increase over time. Furthermore, 
considering that the patient was subjected to clinical 
evaluation only once in 6 months, it is impossible to deter-
mine the exact moment when hypertension appeared. 
Anyhow, in the two previously mentioned reports, the 
appearance of arterial hypertension was evidenced 3 years 
and 6  months, respectively, after the beginning of treat-
ment, confirming the slow and progressive onset of this 
clinical sign.
The cause of this adverse event is not known and only 
some hypotheses have been put forward. Some authors 
have speculated that hypoestrogenism induced by GnRH-a 
treatment may play a role in the elevation of blood pres-
sure levels [7]. Moreover, a hypertensive crisis has been 
described during triptorelin treatment, and it was attributed 
to hypoestrogenism [9]. Animal studies have established 
that a low estrogen level following pharmacological ova-
riectomy by triptorelin decreases the passive diameter of 
the small peripheral arteries and venous capacitance func-
tion and contractility [10]. These responses may provide the 
background mechanism for the increased incidence of arte-
rial hypertension and hot flushes during menopause and 
explain the ability of estrogen substitution to prevent them.
As often signaled, another hypothetical cause of 
hypertension during the treatment with GnRH-a may be 
overweight or obesity. It is well known that general and 
central obesity are predisposing factors for hypertension 
and it is suggested that BMI and obesity are strong pre-
dictors of childhood elevated blood pressure [11]. In this 
case, medical treatment is, at first, not suggested, while 
physicians should establish a comprehensive manage-
ment program emphasizing appropriate nutrition, exer-
cise and behavioral modification. Nevertheless, the BMI 
of our patient did not increase during the treatment, so 
this hypothesis has low clinical significance.
Our patient was diagnosed with CPP and treated with 
GnRH-a every 4  weeks from the age of 7 until she was 
10 years old. During the treatment, she showed typical and 
slight side effects, such as desultory headaches, hot flushes 
and emotional lability. However, she also developed arte-
rial hypertension. Considering her normotensive condition 
before the therapy started, the reversibility of hypertension 
after the end of the treatment and the maintenance of good 
blood pressure values without antihypertensive drugs, we 
can assume that hypoestrogenism played a fundamental 
role in the development of her hypertension.
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In conclusion, although the evidence of hyperten-
sion during treatment with GnRH-a is infrequent and the 
underlying mechanism is still not clear, we recommend 
physicians not only evaluate body weight, pubertal devel-
opment, height velocity and bone age of infants with CPP 
during treatment with GnRH agonist, but also to routinely 
monitor their blood pressure.
Learning points
 – Treatment with GnRH-a (triptorelin) may cause arte-
rial hypertension;
 – The onset of hypertension during treatment with 
GnRH-a (triptorelin) is slow and progressive over time;
 – During treatment with GnRH-a, a strict follow-up is 
necessary in order to evaluate pubertal development, 
height velocity, BMI and blood pressure.
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